Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

LONDON, Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of its previously announced private placement of its securities for total gross proceeds of $5 million, before deducting placement agent fees and other offering expenses.

Read more at prnewswire.com